F.P. Bruno et al. / Journal of Molecular Structure 1036 (2013) 318–325
319
The importance of characterizing the solid-state properties and
the absolute configuration of a drug, which is a critical property in
biological systems as changes in this may alter the response of the
biologic system, has been well documented in the literature. To our
knowledge, the experimental data available in the pharmaceutical
literature on the solid-state properties of TIZ are the melting point
(with two different values reported, viz. 254 °C [9] and 279–281 °C
[10] and the FTIR spectrum (KBr), which was not thoroughly ana-
lyzed and assigned [9,11].
In this report, we describe for the first time, the crystal structure
of TIZ as determined by single crystal X-ray diffraction (SXRD). The
structural features of TIZ are also discussed in the context of its
vibrational [diffuse reflectance infrared Fourier transform (DRIFT)
and FT-Raman], spectroscopic [Solid-state (SSNMR) and solution
(S NMR) nuclear magnetic resonance spectroscopy] and thermal
[differential scanning calorimetry (DSC), thermogravimetry (TG)
and hot stage microscopy (HSM)] properties of this compound.
1. Introduction
Parasitic and viral diseases such as leishmaniasis, trypanosomia-
sis and hepatitis C represent a serious problem to the health and
economy of many countries. There are an estimated annual 1.5–
2.0 million new cases of leishmaniasis, of which approximately
500,000 belong to the potentially fatal visceral form [1]. The
American trypanosomiasis (Chagas disease) affects approximately
15–20 million people from Southern California to Argentina and
Chile; 2–3% of the Latin American (LA) population is infected,
encompassing a burden of about 670,000 Disability Adjusted Life
Years (DALYs), and the morbidity and mortality are more than one
order of magnitude higher than those found for malaria, schistoso-
miasis or leishmaniasis [2]. Current estimates indicate 200,000
new cases every year and an annual mortality of ꢁ50,000 [2]. On
the other hand, Hepatitis C virus (HCV) is a bloodborne infection that
affects nearly 2.2% of the world’s population, or 130 million people
[3]. Approximately 55–85% of newly infected cases progress to chro-
nicity; of those, 20–30% will develop liver fibrosis, cirrhosis, and li-
ver failure and 2–5% will advance to hepatocellular carcinoma [3].
Common chemotherapeutic agents currently used against leish-
maniasis and trypanosomiasis are often inadequate since they re-
quire long courses of administration, may have toxic side effects
or become less effective due to the emergence of resistant strains
[1]. On the other hand, the current standard treatment of care for
hepatitis C (peginterferon and ribavirin) is effective in about half
of all patients treated [4]. Therefore, new, effective and inexpensive
drugs that can be used to treat these diseases are urgently
required.
The thiazolides represent a novel class of anti-infective drugs,
with nitazoxanide [2-acetyloxy-N-(5-nitro-2-thiazolyl)benzamide,
AliniaÒ, NTZ] as the parent compound. NTZ is marketed in the US
and LA for treating diarrhea and enteritis caused by Cryptosporidi-
um spp. or Giardia lamblia in adults and children down to
12 months of age [5]. Following oral administration of a 500 mg
tablet, NTZ is partially absorbed from the gastrointestinal tract
and rapidly hydrolyzed in plasma to form its active circulating
metabolite, tizoxanide (TIZ, Fig. 1.), which is as effective as the par-
ent drug [6]. In fact, both NTZ and TIZ are active against Trypano-
soma cruzi (the causative agent of Chagas disease) and Leishmania
mexicana [1], and the ulcer-causing pathogen Helicobacter pylori
[7]. Also, both NTZ and TIZ are potent inhibitors of hepatitis B virus
(HBV), and in combination with other antiviral agents such as lam-
ivudine or adefovir show synergistic effects [5]. Additionally, NTZ
and TIZ are potent inhibitors of HCV in genotype 1a- and 1b-
derived replicon cells and genotype 2a-cell culture models, and
synergistic effects are observed when TIZ is combined with
interferon [8]. Thus, TIZ is a promising anti-infective agent that
may enhance current or future therapies for leishmaniasis, Chagas
disease and viral hepatitis caused by HBV or HCV.
2. Experimental
2.1. Materials
Tizoxanide, designated hereafter as TIZ-rp, was obtained by acid
hydrolysis (aqueous HCl 37% w/w, 50 °C, 24 h [8]) of NTZ commer-
cial raw powder (99.89% purity) and was used as such to record the
DRIFT, FT-Raman and NMR spectra, as well as the DSC and TG
curves. Single crystals were grown from a filtered hot saturated
solution of TIZ-rp in dimethylformamide. By slow recrystallization
at room temperature (25–30 °C), suitable crystals for X-ray analy-
sis were obtained. All other chemicals and solvents were of analyt-
ical reagent grade or spectroscopic quality.
2.2. Single-crystal X-ray structure determination
Table 1 lists crystal data and refinement parameters for TIZ.
During data-collection (program COLLECT [12]) the crystal was
cooled in a constant stream of nitrogen vapor (Oxford Cryostream,
UK). Program DENZO-SMN [13] was used for data-reduction and
unit cell refinement. Laue symmetry (ꢀ1) indicated the triclinic
crystal system and the value of hE ꢀ 1i = 0.984 indicated the centric
space group P(ꢀ1). The structure was solved by direct methods and
refined by full-matrix least-squares on F2 using programs in the
SHELX-suite [14]. Following isotropic and anisotropic refinement
of the non-hydrogen atoms, all H atoms were located in difference
electron density maps and were subsequently included in a riding
model with isotropic thermal displacement parameters Uiso equal
to 1.2 Ueq of their parent atoms.
2.3. Differential scanning calorimetry (DSC), thermogravimetry (TG)
and hot stage microscopy (HSM)
The DSC and TG measurements were recorded on MDSC 2920
and TG 2950 analyzers (TA Instruments Inc., USA) respectively, at
a heating rate of 10 °C/min under N2 (99.99% purity, flow rate
50 mL/min). For DSC measurements, closed and hermetically-
closed aluminum pans were used. The DSC and TG temperature
axes were calibrated with indium (99.99% purity, m.p. 156.6 °C)
and the Curie point of Ni (358.1 °C), respectively. Empty aluminum
pans were used as references. Samples with mass 1–2 mg were
employed. Data were treated with Universal Analysis 2000 soft-
ware (TA Instruments Inc.).
The physical and morphological changes that occurred during
the process of heating TIZ particles were observed through a
microscope fitted with a Kofler hot-stage (Leitz, Wetzlar, Germany)
at a constant rate of about 8 °C/min from about 25 °C.
Fig. 1. Chemical structure of tizoxanide (TIZ).